Discover the truth in our NeuroQuiet reviews – does this hearing support supplement really deliver on its promises, or is it ...

NLX-101 (F15599) is under development for the treatment of Rett syndrome and depression. The drug candidate is administered by oral route. The drug candidate is a new chemical entity (NCE). The drug ...

Mavoglurant is under development for the treatment of cocaine use disorder, alcohol use disorder and for language learning in young children with fragile X syndrome (FXS). The drug candidate is ...

L-dopa remains the most powerful antiparkinsonian agent, but a minority of treated patients develop disabling motor response complications. Alternatives to L-dopa for initial treatment of ...

Adults with attention-deficit/hyperactivity disorder (ADHD) are more frequently presenting for diagnosis and treatment. Medication is considered to be appropriate ...

After hours: December 30 at 5:54:34 PM EST ...

Company has Deloitte Haskins & Sells LLP as its auditors. As on 30-09-2024, the company has a total of 137.50 Crore shares outstanding.L&T Share Price Today is Rs. 3651.80 as on 01 Jan, 2025, 11:59 AM ...

At close: December 27 at 3:00:00 PM EST ...

It is cleared for both children and adults with AADC (aromatic L-amino acid decarboxylase ... and replaces the human dopa decarboxylase (DDC) gene that is mutated in the disease, allowing dopamine ...

Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma. J. Clin.